HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer
Previous studies have demonstrated that the presence of Hox transcript antisense intergenic RNA (HOTAIR) is correlated with poor survival in several types of cancer, including breast cancer, and promotes tumor metastasis. Currently, little is known regarding the correlation between HOTAIR and chemo-...
Gespeichert in:
| Veröffentlicht in: | Molecular medicine reports 2015-08, Vol.12 (2), p.2211-2216 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2216 |
|---|---|
| container_issue | 2 |
| container_start_page | 2211 |
| container_title | Molecular medicine reports |
| container_volume | 12 |
| creator | WANG, YU WANG, HONGLI SONG, TIEFANG ZOU, YITING JIANG, JING FANG, LEI LI, PEILING |
| description | Previous studies have demonstrated that the presence of Hox transcript antisense intergenic RNA (HOTAIR) is correlated with poor survival in several types of cancer, including breast cancer, and promotes tumor metastasis. Currently, little is known regarding the correlation between HOTAIR and chemo-resistance in cancer. The current study aimed to investigate the role of HOTAIR in epithelial ovarian cancer, and the correlation between HOTAIR and cisplatin resistance. Reverse transcription-quantitative polymerase chain reaction was conducted to detect HOTAIR expression in the ovarian specimens and ovarian carcinoma cell lines. The results indicated that the expression level of HOTAIR was higher in epithelial ovarian cancer tissues than the level in the benign ovarian tissues. The expression level was also higher in late-stage malignant ovarian tumors compared with the level in early-stage tumors. Levels of HOTAIR were also higher in the SKOV-3CDDP/R cisplatin-resistant ovarian carcinoma cell line than in the SKOV-3 cisplatin-sensitive cell line. The knockdown of HOTAIR using siRNAs with transfection reagent suppressed cell proliferation, reduced the invasion ability of the cells and notably, it restored cisplatin-sensitivity of the cisplatin-resistant cells specifically by enhancing cisplatin-induced cytotoxicity and apoptosis in SKOV-3CDDP/R cells. In conclusion, HOTAIR may be used in the development of novel treatments for ovarian cancer, particularly those that are resistant to conventional therapies. |
| doi_str_mv | 10.3892/mmr.2015.3562 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687998781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A425674705</galeid><sourcerecordid>A425674705</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-a87cecadd116231f3b2cb8dc3d084233604a429e2f1ba968fe278b25ee04ee543</originalsourceid><addsrcrecordid>eNptkcFrFDEUhwex2Fo9epWAh3qZNXnJTJLjUlpbKBRkPYdM5k1NmZmMSVbwv2-GXYtKySHh5Xs_fvBV1QdGN1xp-DJNcQOUNRvetPCqOmNSs5pTKl4f36C1PK3epvRIadtAo99Up9AoEC1rz6rdzf1ue_uN-EQsWULGOXs7kmzjA2YyhEjyDyQ5os1T-SNhIM6nZbTZz3XE5FO26_iXjd7OxNnZYXxXnQx2TPj-eJ9X36-vdpc39d3919vL7V3tSo9cWyUdOtv3jLXA2cA7cJ3qHe-pEsB5S4UVoBEG1lndqgFBqg4aRCoQG8HPq8-H3CWGn3tM2Uw-ORxHO2PYJ8NaJbVWUrGCfvoPfQz7OJd2hmkOQjJJ_6Ie7IjGz0PI0bo11GwFNK0UkjaF2rxAldPj5F2YcfBl_s9CfVhwMaQUcTBL9JONvw2jZrVoikWzWjSrxcJ_PJbddxP2z_QfbQW4OABpsXPv-5CemZJUM6gp1ACM8Sej6KLG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932471701</pqid></control><display><type>article</type><title>HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>WANG, YU ; WANG, HONGLI ; SONG, TIEFANG ; ZOU, YITING ; JIANG, JING ; FANG, LEI ; LI, PEILING</creator><creatorcontrib>WANG, YU ; WANG, HONGLI ; SONG, TIEFANG ; ZOU, YITING ; JIANG, JING ; FANG, LEI ; LI, PEILING</creatorcontrib><description>Previous studies have demonstrated that the presence of Hox transcript antisense intergenic RNA (HOTAIR) is correlated with poor survival in several types of cancer, including breast cancer, and promotes tumor metastasis. Currently, little is known regarding the correlation between HOTAIR and chemo-resistance in cancer. The current study aimed to investigate the role of HOTAIR in epithelial ovarian cancer, and the correlation between HOTAIR and cisplatin resistance. Reverse transcription-quantitative polymerase chain reaction was conducted to detect HOTAIR expression in the ovarian specimens and ovarian carcinoma cell lines. The results indicated that the expression level of HOTAIR was higher in epithelial ovarian cancer tissues than the level in the benign ovarian tissues. The expression level was also higher in late-stage malignant ovarian tumors compared with the level in early-stage tumors. Levels of HOTAIR were also higher in the SKOV-3CDDP/R cisplatin-resistant ovarian carcinoma cell line than in the SKOV-3 cisplatin-sensitive cell line. The knockdown of HOTAIR using siRNAs with transfection reagent suppressed cell proliferation, reduced the invasion ability of the cells and notably, it restored cisplatin-sensitivity of the cisplatin-resistant cells specifically by enhancing cisplatin-induced cytotoxicity and apoptosis in SKOV-3CDDP/R cells. In conclusion, HOTAIR may be used in the development of novel treatments for ovarian cancer, particularly those that are resistant to conventional therapies.</description><identifier>ISSN: 1791-2997</identifier><identifier>EISSN: 1791-3004</identifier><identifier>DOI: 10.3892/mmr.2015.3562</identifier><identifier>PMID: 25824616</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Antineoplastic Agents - pharmacology ; Antisense RNA ; Apoptosis ; Apoptosis - drug effects ; Benign ; Breast cancer ; Cancer therapies ; Carcinoma, Ovarian Epithelial ; Care and treatment ; Case-Control Studies ; Cell Line, Tumor ; Cell proliferation ; Cell Proliferation - drug effects ; chemoresistance ; Chemotherapy ; Cisplatin ; Cisplatin - pharmacology ; Cytotoxicity ; Drug Resistance, Neoplasm - genetics ; Female ; Gene expression ; Gene Expression Regulation, Neoplastic ; Genetic aspects ; Health aspects ; Hox transcript antisense intergenic RNA ; Humans ; Hypotheses ; invasion ; long noncoding RNA ; Medical prognosis ; Metastases ; Neoplasm Staging ; Neoplasms, Glandular and Epithelial - drug therapy ; Neoplasms, Glandular and Epithelial - genetics ; Neoplasms, Glandular and Epithelial - metabolism ; Neoplasms, Glandular and Epithelial - pathology ; Ovarian cancer ; Ovarian carcinoma ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Pathogenesis ; Patients ; Polymerase chain reaction ; Prognosis ; Reverse transcription ; Ribonucleic acid ; RNA ; RNA, Long Noncoding - antagonists & inhibitors ; RNA, Long Noncoding - genetics ; RNA, Long Noncoding - metabolism ; RNA, Small Interfering - genetics ; RNA, Small Interfering - metabolism ; Roles ; Signal Transduction ; siRNA ; Stem cells ; Studies ; Surgery ; Transfection ; Tumor cell lines ; Tumors</subject><ispartof>Molecular medicine reports, 2015-08, Vol.12 (2), p.2211-2216</ispartof><rights>Copyright © 2015, Spandidos Publications</rights><rights>COPYRIGHT 2015 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-a87cecadd116231f3b2cb8dc3d084233604a429e2f1ba968fe278b25ee04ee543</citedby><cites>FETCH-LOGICAL-c525t-a87cecadd116231f3b2cb8dc3d084233604a429e2f1ba968fe278b25ee04ee543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,5555,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25824616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WANG, YU</creatorcontrib><creatorcontrib>WANG, HONGLI</creatorcontrib><creatorcontrib>SONG, TIEFANG</creatorcontrib><creatorcontrib>ZOU, YITING</creatorcontrib><creatorcontrib>JIANG, JING</creatorcontrib><creatorcontrib>FANG, LEI</creatorcontrib><creatorcontrib>LI, PEILING</creatorcontrib><title>HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer</title><title>Molecular medicine reports</title><addtitle>Mol Med Rep</addtitle><description>Previous studies have demonstrated that the presence of Hox transcript antisense intergenic RNA (HOTAIR) is correlated with poor survival in several types of cancer, including breast cancer, and promotes tumor metastasis. Currently, little is known regarding the correlation between HOTAIR and chemo-resistance in cancer. The current study aimed to investigate the role of HOTAIR in epithelial ovarian cancer, and the correlation between HOTAIR and cisplatin resistance. Reverse transcription-quantitative polymerase chain reaction was conducted to detect HOTAIR expression in the ovarian specimens and ovarian carcinoma cell lines. The results indicated that the expression level of HOTAIR was higher in epithelial ovarian cancer tissues than the level in the benign ovarian tissues. The expression level was also higher in late-stage malignant ovarian tumors compared with the level in early-stage tumors. Levels of HOTAIR were also higher in the SKOV-3CDDP/R cisplatin-resistant ovarian carcinoma cell line than in the SKOV-3 cisplatin-sensitive cell line. The knockdown of HOTAIR using siRNAs with transfection reagent suppressed cell proliferation, reduced the invasion ability of the cells and notably, it restored cisplatin-sensitivity of the cisplatin-resistant cells specifically by enhancing cisplatin-induced cytotoxicity and apoptosis in SKOV-3CDDP/R cells. In conclusion, HOTAIR may be used in the development of novel treatments for ovarian cancer, particularly those that are resistant to conventional therapies.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Antisense RNA</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Benign</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Ovarian Epithelial</subject><subject>Care and treatment</subject><subject>Case-Control Studies</subject><subject>Cell Line, Tumor</subject><subject>Cell proliferation</subject><subject>Cell Proliferation - drug effects</subject><subject>chemoresistance</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - pharmacology</subject><subject>Cytotoxicity</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Hox transcript antisense intergenic RNA</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>invasion</subject><subject>long noncoding RNA</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Glandular and Epithelial - drug therapy</subject><subject>Neoplasms, Glandular and Epithelial - genetics</subject><subject>Neoplasms, Glandular and Epithelial - metabolism</subject><subject>Neoplasms, Glandular and Epithelial - pathology</subject><subject>Ovarian cancer</subject><subject>Ovarian carcinoma</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Polymerase chain reaction</subject><subject>Prognosis</subject><subject>Reverse transcription</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Long Noncoding - antagonists & inhibitors</subject><subject>RNA, Long Noncoding - genetics</subject><subject>RNA, Long Noncoding - metabolism</subject><subject>RNA, Small Interfering - genetics</subject><subject>RNA, Small Interfering - metabolism</subject><subject>Roles</subject><subject>Signal Transduction</subject><subject>siRNA</subject><subject>Stem cells</subject><subject>Studies</subject><subject>Surgery</subject><subject>Transfection</subject><subject>Tumor cell lines</subject><subject>Tumors</subject><issn>1791-2997</issn><issn>1791-3004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkcFrFDEUhwex2Fo9epWAh3qZNXnJTJLjUlpbKBRkPYdM5k1NmZmMSVbwv2-GXYtKySHh5Xs_fvBV1QdGN1xp-DJNcQOUNRvetPCqOmNSs5pTKl4f36C1PK3epvRIadtAo99Up9AoEC1rz6rdzf1ue_uN-EQsWULGOXs7kmzjA2YyhEjyDyQ5os1T-SNhIM6nZbTZz3XE5FO26_iXjd7OxNnZYXxXnQx2TPj-eJ9X36-vdpc39d3919vL7V3tSo9cWyUdOtv3jLXA2cA7cJ3qHe-pEsB5S4UVoBEG1lndqgFBqg4aRCoQG8HPq8-H3CWGn3tM2Uw-ORxHO2PYJ8NaJbVWUrGCfvoPfQz7OJd2hmkOQjJJ_6Ie7IjGz0PI0bo11GwFNK0UkjaF2rxAldPj5F2YcfBl_s9CfVhwMaQUcTBL9JONvw2jZrVoikWzWjSrxcJ_PJbddxP2z_QfbQW4OABpsXPv-5CemZJUM6gp1ACM8Sej6KLG</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>WANG, YU</creator><creator>WANG, HONGLI</creator><creator>SONG, TIEFANG</creator><creator>ZOU, YITING</creator><creator>JIANG, JING</creator><creator>FANG, LEI</creator><creator>LI, PEILING</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150801</creationdate><title>HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer</title><author>WANG, YU ; WANG, HONGLI ; SONG, TIEFANG ; ZOU, YITING ; JIANG, JING ; FANG, LEI ; LI, PEILING</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-a87cecadd116231f3b2cb8dc3d084233604a429e2f1ba968fe278b25ee04ee543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Antisense RNA</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Benign</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Ovarian Epithelial</topic><topic>Care and treatment</topic><topic>Case-Control Studies</topic><topic>Cell Line, Tumor</topic><topic>Cell proliferation</topic><topic>Cell Proliferation - drug effects</topic><topic>chemoresistance</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - pharmacology</topic><topic>Cytotoxicity</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Hox transcript antisense intergenic RNA</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>invasion</topic><topic>long noncoding RNA</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Glandular and Epithelial - drug therapy</topic><topic>Neoplasms, Glandular and Epithelial - genetics</topic><topic>Neoplasms, Glandular and Epithelial - metabolism</topic><topic>Neoplasms, Glandular and Epithelial - pathology</topic><topic>Ovarian cancer</topic><topic>Ovarian carcinoma</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Polymerase chain reaction</topic><topic>Prognosis</topic><topic>Reverse transcription</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Long Noncoding - antagonists & inhibitors</topic><topic>RNA, Long Noncoding - genetics</topic><topic>RNA, Long Noncoding - metabolism</topic><topic>RNA, Small Interfering - genetics</topic><topic>RNA, Small Interfering - metabolism</topic><topic>Roles</topic><topic>Signal Transduction</topic><topic>siRNA</topic><topic>Stem cells</topic><topic>Studies</topic><topic>Surgery</topic><topic>Transfection</topic><topic>Tumor cell lines</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WANG, YU</creatorcontrib><creatorcontrib>WANG, HONGLI</creatorcontrib><creatorcontrib>SONG, TIEFANG</creatorcontrib><creatorcontrib>ZOU, YITING</creatorcontrib><creatorcontrib>JIANG, JING</creatorcontrib><creatorcontrib>FANG, LEI</creatorcontrib><creatorcontrib>LI, PEILING</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular medicine reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WANG, YU</au><au>WANG, HONGLI</au><au>SONG, TIEFANG</au><au>ZOU, YITING</au><au>JIANG, JING</au><au>FANG, LEI</au><au>LI, PEILING</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer</atitle><jtitle>Molecular medicine reports</jtitle><addtitle>Mol Med Rep</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>12</volume><issue>2</issue><spage>2211</spage><epage>2216</epage><pages>2211-2216</pages><issn>1791-2997</issn><eissn>1791-3004</eissn><abstract>Previous studies have demonstrated that the presence of Hox transcript antisense intergenic RNA (HOTAIR) is correlated with poor survival in several types of cancer, including breast cancer, and promotes tumor metastasis. Currently, little is known regarding the correlation between HOTAIR and chemo-resistance in cancer. The current study aimed to investigate the role of HOTAIR in epithelial ovarian cancer, and the correlation between HOTAIR and cisplatin resistance. Reverse transcription-quantitative polymerase chain reaction was conducted to detect HOTAIR expression in the ovarian specimens and ovarian carcinoma cell lines. The results indicated that the expression level of HOTAIR was higher in epithelial ovarian cancer tissues than the level in the benign ovarian tissues. The expression level was also higher in late-stage malignant ovarian tumors compared with the level in early-stage tumors. Levels of HOTAIR were also higher in the SKOV-3CDDP/R cisplatin-resistant ovarian carcinoma cell line than in the SKOV-3 cisplatin-sensitive cell line. The knockdown of HOTAIR using siRNAs with transfection reagent suppressed cell proliferation, reduced the invasion ability of the cells and notably, it restored cisplatin-sensitivity of the cisplatin-resistant cells specifically by enhancing cisplatin-induced cytotoxicity and apoptosis in SKOV-3CDDP/R cells. In conclusion, HOTAIR may be used in the development of novel treatments for ovarian cancer, particularly those that are resistant to conventional therapies.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>25824616</pmid><doi>10.3892/mmr.2015.3562</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1791-2997 |
| ispartof | Molecular medicine reports, 2015-08, Vol.12 (2), p.2211-2216 |
| issn | 1791-2997 1791-3004 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1687998781 |
| source | Spandidos Publications Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - pharmacology Antisense RNA Apoptosis Apoptosis - drug effects Benign Breast cancer Cancer therapies Carcinoma, Ovarian Epithelial Care and treatment Case-Control Studies Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects chemoresistance Chemotherapy Cisplatin Cisplatin - pharmacology Cytotoxicity Drug Resistance, Neoplasm - genetics Female Gene expression Gene Expression Regulation, Neoplastic Genetic aspects Health aspects Hox transcript antisense intergenic RNA Humans Hypotheses invasion long noncoding RNA Medical prognosis Metastases Neoplasm Staging Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - genetics Neoplasms, Glandular and Epithelial - metabolism Neoplasms, Glandular and Epithelial - pathology Ovarian cancer Ovarian carcinoma Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Pathogenesis Patients Polymerase chain reaction Prognosis Reverse transcription Ribonucleic acid RNA RNA, Long Noncoding - antagonists & inhibitors RNA, Long Noncoding - genetics RNA, Long Noncoding - metabolism RNA, Small Interfering - genetics RNA, Small Interfering - metabolism Roles Signal Transduction siRNA Stem cells Studies Surgery Transfection Tumor cell lines Tumors |
| title | HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T11%3A24%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HOTAIR%20is%20a%20potential%20target%20for%20the%20treatment%20of%20cisplatin-resistant%20ovarian%20cancer&rft.jtitle=Molecular%20medicine%20reports&rft.au=WANG,%20YU&rft.date=2015-08-01&rft.volume=12&rft.issue=2&rft.spage=2211&rft.epage=2216&rft.pages=2211-2216&rft.issn=1791-2997&rft.eissn=1791-3004&rft_id=info:doi/10.3892/mmr.2015.3562&rft_dat=%3Cgale_proqu%3EA425674705%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932471701&rft_id=info:pmid/25824616&rft_galeid=A425674705&rfr_iscdi=true |